

(12) International Application Status Report

Received at International Bureau: 21 June 2023 (21.06.2023)

Information valid as of: 02 November 2023 (02.11.2023)

Report generated on: 25 October 2024 (25.10.2024)

(10) Publication number:

WO2023/239227

(43) Publication date:

14 December 2023 (14.12.2023)

(26) Publication language:

Korean (KO)

(21) Application Number:

PCT/KR2023/008062

(22) Filing Date:

12 June 2023 (12.06.2023)

(25) Filing language:

Korean (KO)

(31) Priority number(s):

10-2022-0070989 (KR)

(31) Priority date(s):

10 June 2022 (10.06.2022)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

10-2023-0074884 (KR)

12 June 2023 (12.06.2023)

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

C07D 403/12 (2006.01); **A61K 31/498** (2006.01); **A61K 31/506** (2006.01); **A61K 31/4985** (2006.01); **A61P 11/00** (2006.01); **A61P 43/00** (2006.01); **C07D 403/06** (2006.01); **C07D 401/12** (2006.01); **C07D 471/04** (2006.01); **C07D 403/14** (2006.01)

(71) Applicant(s):

SAPIENSBIO INC. [KR/KR]; 910-ho, 148 Sagimakgol-ro, Jungwon-gu Seongnam-si Gyeonggi-do 13207 (KR) *(for all designated states)*

(72) Inventor(s):

YOON, Dong-Oh; 910-ho, 148 Sagimakgol-ro, Jungwon-gu Seongnam-si Gyeonggi-do 13207 (KR)
RYU, Incheol; 910-ho, 148 Sagimakgol-ro, Jungwon-gu Seongnam-si Gyeonggi-do 13207 (KR)
RYOO, Kanghyun; 910-ho, 148 Sagimakgol-ro, Jungwon-gu Seongnam-si Gyeonggi-do 13207 (KR)
LEE, Hyunseung; 910-ho, 148 Sagimakgol-ro, Jungwon-gu Seongnam-si Gyeonggi-do 13207 (KR)
PARK, Yeonkyeong; 910-ho, 148 Sagimakgol-ro, Jungwon-gu Seongnam-si Gyeonggi-do 13207 (KR)
AN, Sihyeon; 909-ho, 148 Sagimakgol-ro, Jungwon-gu Seongnam-si Gyeonggi-do 13207 (KR)
LEE, Myongwoo; 910-ho, 148 Sagimakgol-ro, Jungwon-gu Seongnam-si Gyeonggi-do 13207 (KR)

(74) Agent(s):

LEE, Myoung-Jin; 13th Floor, 445, Teheran-ro, Gangnam-Gu, Seoul 06158 (KR)

(54) Title (EN): NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT

(54) Title (FR): NOUVEAU COMPOSÉ ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT EN TANT QUE PRINCIPE ACTIF

(54) Title (KO): 신규한 화합물 및 이를 유효성분으로 포함하는 약학적 조성물

(57) Abstract:

(EN): The present invention relates to a novel compound that regulates the function and differentiation of the cytoskeleton, which is involved in pulmonary fibrosis, and thus is useful in the preparation of drugs that can treat associated diseases. It has been identified that a novel compound or a pharmaceutically acceptable salt thereof, according to the present invention, has the effect of regulating actin polymerization required for the formation of cytoskeleton, and that the expression of α -SMA and F-actin, which are main factors causing fibrosis, are effectively inhibited in human lung tissue-derived fibroblasts (MRC5). In addition, it has been identified that when activated macrophages are treated with the compound, the level of inflammation of inflammatory cytokines, caused by macrophages, is reduced. Therefore, a novel compound according to the present invention is expected to be effectively used, as a preparation having the effect of inhibiting or alleviating fibrosis of the lungs, in the prevention and treatment of diseases associated with pulmonary fibrosis.

(FR): La présente invention concerne un nouveau composé qui régule la fonction et la différenciation du cytosquelette, qui est impliqué dans la fibrose pulmonaire, et est ainsi utile dans la préparation de médicaments qui peuvent traiter des maladies

associées. Il a été identifié qu'un nouveau composé ou un sel pharmaceutiquement acceptable de celui-ci, selon la présente invention, a pour effet de réguler la polymérisation de l'actine requise pour la formation du cytosquelette, et que l'expression de l' α -SMA et de la F-actine, qui sont des facteurs principaux provoquant la fibrose, sont inhibées de manière efficace dans les fibroblastes dérivés du tissu pulmonaire humain (MRC5). De plus, il a été identifié que le traitement des macrophages activés avec le composé, permet de réduire le niveau d'inflammation de cytokines inflammatoires, provoqué par les macrophages. Par conséquent, un nouveau composé selon la présente invention est censé être utilisé de manière efficace, en tant que préparation ayant pour effet d'inhiber ou de soulager la fibrose des poumons, dans la prévention et le traitement de maladies associées à la fibrose pulmonaire.

(KO): 본 발명은 폐 섬유화 과정에 관여하는 세포골격 (cytoskeleton)의 기능 및 분화를 조절함으로써 관련 질병을 치료할 수 있는 의약 제조에 유용한 신규한 화합물에 관한 것이다. 본 발명에 따른 신규한 화합물 또는 이의 약학적으로 허용 가능한 염은 세포골격의 형성에 필요한 액틴 중합을 조절하는 효과가 있음을 확인하였으며, 인간 폐조직 유래 섬유아세포 (MRC5)에서 섬유화의 주요 원인 인자인 α -SMA과 F-액틴의 발현을 효과적으로 억제하는 것을 확인하였다. 또한, 활성화된 대식세포에 상기 화합물 처리시 대식세포에 의한 염증성 사이토카인의 수준이 감소하는 것이 확인되었다. 따라서, 본 발명에 따른 신규한 화합물은 폐의 섬유화를 억제 내지 개선하는 효과를 갖는 제제로서 폐 섬유증 관련 질환의 예방 및 치료에 유용하게 활용될 것으로 기대된다.

International search report:

Received at International Bureau: 14 September 2023 (14.09.2023) [KR]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM